15 результати
The present invention relates to the use of triazine and pyrimidine compounds for obtaining medicaments that reverse resistance to anti-cancer and anti-malarial agents.
A number of triazine and pyrimidine compounds having valuable pharmacological properties are known in the literature. Some of these
FIELD OF INVENTION
The present invention relates to dihydroartemisinin and dihydroartemisitene dimers and their use in the treatment of cancer and as antiprotzoal agents.
BACKGROUND OF THE INVENTION
Cancer deaths in the U.S. alone were over 500,000 in 2001, and in spite of many advances, cancer
FIELD OF THE INVENTION
The present invention relates to dihydroartemisinin and dihydroartemisitene dimers and their use in the treatment of cancer and as antiprotzoal agents.
BACKGROUND OF THE INVENTION
Cancer deaths in the U.S. alone were over 500,000 in 2001, and in spite of many advances, cancer
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention may be used as
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the formation of a novel, stable C-10 carba trioxane dimer that may easily be transformed into different trioxane dimers. Some of these dimers are 10 times more antimalarially potent in vitro than artemisinin.
FIELD OF INVENTION
The present disclosure concerns methods for treating cancer.
BACKGROUND
The human body has evolved complex mechanisms to perpetuate and protect itself. Sometimes, however, those mechanisms go awry, and either exacerbate or, indeed, cause serious pathologies such as cancer. Despite
This invention relates to tumor necrosis factors (TNF) and to compounds having enhanced cytotoxic or cytostatic activity for transformed cells. More particularly, the invention relates to a process for producing tumor necrosis factor-like polypeptides. Most particularly, this invention relates to
FIELD OF THE INVENTION
This invention relates to compositions and methods for treating malaria. Specifically, this invention relates to pharmaceutical compositions including spiro and dispiro trioxolanes, and methods of their use and manufacture.
BACKGROUND OF THE INVENTION
Malaria is an acute and
FIELD OF THE INVENTION
This invention relates to compositions and methods for treating malaria. Specifically, this invention relates to pharmaceutical compositions including spiro and dispiro trioxolanes, and methods of their use and manufacture.
BACKGROUND OF THE INVENTION
Malaria is an acute and
FIELD OF THE INVENTION
This invention relates to compositions and methods for treating malaria. Specifically, this invention relates to pharmaceutical compositions including spiro and dispiro trioxolanes, and methods of their use and manufacture.
BACKGROUND OF THE INVENTION
Malaria is an acute and
FIELD OF INVENTION
The present invention relates to dihydroartemisinin and dihydroartemisitene dimers and their use in the treatment of cancer and as antiprotzoal agents.
BACKGROUND OF THE INVENTION
Cancer deaths in the U.S. alone were over 500,000 in 2001, and in spite of many advances, cancer
FIELD OF THE INVENTION
The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of Andrographolide,
FIELD OF THE INVENTION
The present invention, in some embodiments thereof, relates to fixed dose combination (FDC) compositions, more particularly, but not exclusively, to compositions comprising at least one cannabinoid as a plant isolate or synthetic, in essentially pure form or as a component of
FIELD OF THE INVENTION
The present invention, in some embodiments thereof, relates to fixed dose combination (FDC) compositions, more particularly, but not exclusively, to compositions comprising at least one cannabinoid as a plant isolate or synthetic, in essentially pure form or as a component of
This application is a U.S. national stage of PCT/EP2010/068924 filed on Dec. 6, 2010 which claims priority to and the benefit of European Application No. EP09180666.1 on Dec. 23, 2009, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to